Business Context and Reporting Period
This Form 8-K is filed by Neuralstem, Inc. (Note: Metadata listed "Palisade Bio, Inc." but the filing text identifies the registrant as Neuralstem, Inc.) for the reporting period ending June 30, 2009. The report details the entry into a material definitive agreement regarding a private placement offering of securities.
Key Financial Metrics and Transaction Details
- Gross Proceeds: $1,000,000
- Net Proceeds: $930,000 (after deducting placement agent fees)
- Placement Agent Fee: $70,000 cash (7% of gross proceeds) plus a warrant to purchase 40,000 shares
- Offering Price: $1.25 per unit
- Securities Issued:
- 800,000 shares of Common Stock
- 2,400,000 Warrants (Series D, E, and F; 800,000 each)
- 40,000 Placement Agent Warrants
- Warrant Exercise Prices: $1.25 for Series D, E, and F; $1.5625 for Placement Agent Warrant
- Warrant Terms: Series D (1 year), Series E (3 years), Series F (5 years), Placement Agent (5 years)
Material Changes
The filing reports a material change in the company's capital structure due to the closing of the offering on June 30, 2009. The company issued new equity and warrants to institutional investors. The filing text does not provide comparative financial data (revenue, profit, or cash flow) for prior periods as this is a current report on a specific transaction rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Future Participation: Purchasers are entitled to participate in any subsequent offering of the Company's securities for a period of 12 months following the closing.
- Adjustments: Warrants contain provisions for adjustment of purchase price and share count in the event of stock splits, dividends, rights offerings, pro-rata distributions, or fundamental transactions.
- Price Protection: The warrants do not contain provisions regarding subsequent securities issuances or "price protection provisions."
- Registration: The offering was registered under a Form S-3 filed in September 2008.
Investor Verification Checklist
- Verify the exact number of outstanding shares post-issuance to assess dilution impact.
- Confirm the use of the $930,000 net proceeds as disclosed in the press release (Exhibit 99.1).
- Review the specific terms of the 12-month participation right for institutional investors.
- Check for any subsequent filings regarding the exercise of the Series D, E, and F warrants.